Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA7 | P43166 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.47 |
| ▸ | XDH | P47989 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4040319 | 0.81 | GABRA1 (0.40) | CA1CA2CA12CA9CA14 | |
| SCHEMBL3149483 | 0.81 | CA12 (0.51) | CA1CA2CA12CA7CA9 | |
| SCHEMBL1100872 | 0.79 | CA1 (0.48) | CA1CA2CA12CA7CA9 | |
| SCHEMBL128693 | 0.79 | CA1 (0.48) | CA1CA2CA12CA7CA9 | |
| SCHEMBL7165180 | 0.79 | CA1 (0.53) | CA1CA2CA12CA7CA9 | |
| SCHEMBL3391247 | 0.79 | ALDH1A1 (0.41) | MAPTALDH1A1HPGDGAARAB9A | |
| SCHEMBL7975142 | 0.78 | HPGD (0.32) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL4286215 | 0.78 | CA1 (0.47) | CA1CA2CA12CA7CA9 | |
| SCHEMBL426458 | 0.78 | HDAC6 (0.46) | CA2TSHRHPGDGAAHTT | |
| SCHEMBL3964444 | 0.78 | CA1 (0.47) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113767105-A | Heterocyclic compounds as inhibitors of monoacylglycerol lipases (MAGL) | 豪夫迈·罗氏有限公司 | 2021-12-07 | — | — | CN | disclosed |
| US-10189839-B2 | Tricyclic imidazole compounds as inhibitors of tryptophan hydroxylase | ACTELION PHARMACEUTICALS LTD (CH) | 2019-01-29 | — | — | US | disclosed |
| CN-108558871-A | Novel tricyclic compound as anticancer agent | 百时美施贵宝公司 | 2018-09-21 | — | — | CN | disclosed |
| CN-105492444-B | Tricyclic pyridine-carboxamide derivatives as ROCK inhibitors | 百时美施贵宝公司 | 2018-09-07 | — | — | CN | disclosed |
| CN-108349930-A | Substituted Tricycles and Methods of Use | 艾伯维公司 | 2018-07-31 | — | — | CN | disclosed |
| CN-106029663-B | Tricyclic compounds as anticancer agents | 百时美施贵宝公司 | 2018-06-01 | — | — | CN | disclosed |
| EP-3071578-B1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-01-10 | — | — | EP | disclosed |
| CN-105143193-B | Biaryl or heterocyclic biaryl substituted cyclohexene derivative compounds as CETP inhibitors | 株式会社钟根堂 | 2017-12-15 | — | — | CN | disclosed |
| US-9765092-B2 | Tricyclic piperidine compounds | ACTELION PHARMACEUTICALS LTD (CH) | 2017-09-19 | — | — | US | disclosed |
| EP-3071567-B1 | TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE | ACTELION PHARMACEUTICALS LTD (CH) | 2017-09-06 | — | — | EP | disclosed |
| CN-1210257-C | Substituted aromatic-ring compounds, process for producing the same, and us | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2005-07-13 | — | — | CN | disclosed |
| EP-1539164-A1 | 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA Pharma AG (DE) | 2005-06-15 | — | — | EP | disclosed |
| EP-1536798-A1 | 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA Pharma AG (DE) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004019945-A1 | 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA PHARMA AG (DE) | 2004-03-11 | — | — | WO | disclosed |
| WO-2004019944-A1 | 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA PHARMA AG (DE) | 2004-03-11 | — | — | WO | disclosed |
| CN-1374946-A | Substituted aromatic-ring compounds, process for producing the same, and us | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-10-16 | — | — | CN | disclosed |
| US-5389642-A | Exhibit antagonistic properties toward angiotensin(II); useful for treatment of hypertensioni, aldosteronism, cardiac insufficiency, increased intraocular pressure and disorders of the central nervous system | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-02-14 | — | — | US | disclosed |
| CN-1094044-A | Imidazopyridine | MERCK PATENT GMBH (DE) | 1994-10-26 | — | — | CN | disclosed |
| EP-0602521-A1 | Imidazopyridines | MERCK PATENT GmbH (DE) | 1994-06-22 | — | — | EP | disclosed |
| EP-0006735-A1 | Secondary amines, their preparation, pharmaceutical compositions containing them and their use | BEECHAM GROUP PLC (GB) | 1980-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189839-B2 | Tricyclic imidazole compounds as inhibitors of tryptophan hydroxylase | TPH1, TPH2, MAOB | CA1 2622/4885CA2 2398/4885CA12 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.